Lawyers may seek judicial review of panel reviewing paroxetineBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7390.618 (Published 22 March 2003) Cite this as: BMJ 2003;326:618
- Roger Dobson
Lawyers acting for more than 4000 people who allege side effects from the antidepressant drug paroxetine (Seroxat) may seek a judicial review over the composition of a review panel set up to look at the drug and other selective serotonin reuptake inhibitors (SSRIs).
The lawyers say they are unhappy that some of the committee members have links with the drugs industry. It has been claimed that some members of the review team, which is drawn from the Committee on Safety of Medicines, have shares in GlaxoSmithKline, the maker of paroxetine (Guardian 17 March: 1).
The review of the side effects of the SSRIs was announced at the end of last year and came in the wake of reports from patients of severe withdrawal symptoms.
The Department of Health …